Patents by Inventor David C. Myles
David C. Myles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220370421Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.Type: ApplicationFiled: December 6, 2021Publication date: November 24, 2022Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
-
Publication number: 20220265616Abstract: Provided herein are methods of administering estrogen receptor antagonists for use in treatment of cancer. In some embodiments, estrogen receptor antagonists provided herein are tetrahydro pyrido[3,4-b] indole compounds. In some embodiments, provided antagonists are complete estrogen receptor antagonists.Type: ApplicationFiled: July 6, 2020Publication date: August 25, 2022Inventors: Cyrus L. Harmon, Peter J. Kushner, David C. Myles, Leslie Hodges Gallagher, Richard Sun
-
Patent number: 11229630Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.Type: GrantFiled: April 17, 2020Date of Patent: January 25, 2022Assignee: Olema Pharmaceuticals, Inc.Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
-
Publication number: 20210059991Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.Type: ApplicationFiled: April 17, 2020Publication date: March 4, 2021Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
-
Patent number: 10624878Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.Type: GrantFiled: April 23, 2019Date of Patent: April 21, 2020Assignee: Olema Pharmaceuticals, Inc.Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
-
Publication number: 20190247372Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.Type: ApplicationFiled: April 23, 2019Publication date: August 15, 2019Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
-
Patent number: 10292971Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.Type: GrantFiled: September 29, 2016Date of Patent: May 21, 2019Assignee: Olema Pharmaceuticals, Inc.Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
-
Publication number: 20180289679Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.Type: ApplicationFiled: September 29, 2016Publication date: October 11, 2018Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
-
Publication number: 20170362210Abstract: The present disclosure provides a compound of Formula I: or a pharmaceutically acceptable salt wherein X, R1-R8, Y1-Y5, m, n, p, and q are defined herein. The novel 2H-chromene compounds are useful for the modulation of disorders mediated by estrogen, and other disorders, as described herein. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions.Type: ApplicationFiled: August 14, 2017Publication date: December 21, 2017Applicant: PFIZER INC.Inventors: Peter J. KUSHNER, David C. MYLES, Cyrus L. HARMON, Leslie Carol HODGES GALLAGHER
-
Publication number: 20160311805Abstract: The present disclosure provides a compound of Formula I: or a pharmaceutically acceptable salt wherein X, R1-R8, Y1-Y5, m, n, p, and q are defined herein. The novel 2H-chromene compounds are useful for the modulation of disorders mediated by estrogen, and other disorders, as described herein. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions.Type: ApplicationFiled: April 22, 2016Publication date: October 27, 2016Applicant: PFIZER INC.Inventors: Peter J. KUSHNER, David C. MYLES, Cyrus L. HARMON, Leslie Carol HODGES GALLAGHER
-
Publication number: 20150197506Abstract: Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans.Type: ApplicationFiled: March 17, 2015Publication date: July 16, 2015Applicant: OLEMA PHARMACEUTICALS, INC.Inventors: Peter J. Kushner, David C. Myles, Cyrus L. Harmon, Leslie Carol Hodges Gallagher
-
Patent number: 9018244Abstract: Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans.Type: GrantFiled: December 17, 2012Date of Patent: April 28, 2015Assignee: Olema Pharmaceuticals, Inc.Inventors: Peter J. Kushner, David C. Myles, Cyrus L. Harmon, Leslie Carol Hodges Gallagher
-
Patent number: 8193241Abstract: 6- and 7-substituted coumarin and related 6- and 7-substituted 1H-quinolin-2-one compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the 7-substituted coumarin and related 7-substituted 1H-quinolin-2-one compounds mimic or exceed the high level of pharmacological activity of discodermolide. In other embodiments, their preparation involves more readily available materials, higher yield processes and/or simpler synthetic sequences. In yet other embodiments, the compounds of the invention represent structurally simpler, therapeutically active analogues of discodermolide than heretofore known and may be useful as microtubule stabilizers and, inter alia, for treating and/or preventing cancer and other diseases, disorders, and/or conditions mediated by the stabilization of microtubules.Type: GrantFiled: November 15, 2010Date of Patent: June 5, 2012Assignee: The Trustees Of The University Of PennsylvaniaInventors: Amos B. Smith, III, Simon J. Shaw, David C. Myles
-
Patent number: 8063021Abstract: Compounds according to formula I wherein m is 0 or 1; X is and R1, R2, R3 R4, and R5 are as defined herein, are useful as anti-infective agents.Type: GrantFiled: June 30, 2004Date of Patent: November 22, 2011Assignee: Kosan Biosciences IncorporatedInventors: Yong Li, Yandong Li, Yan Zhu, Chaitan Khosla, David C. Myles
-
Publication number: 20110172220Abstract: 6- and 7-substituted coumarin and related 6- and 7-substituted 1H-quinolin-2-one compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the 7-substituted coumarin and related 7-substituted 1H-quinolin-2-one compounds mimic or exceed the high level of pharmacological activity of discodermolide. In other embodiments, their preparation involves more readily available materials, higher yield processes and/or simpler synthetic sequences. In yet other embodiments, the compounds of the invention represent structurally simpler, therapeutically active analogues of discodermolide than heretofore known and may be useful as microtubule stabilizers and, inter alia, for treating and/or preventing cancer and other diseases, disorders, and/or conditions mediated by the stabilization of microtubules.Type: ApplicationFiled: November 15, 2010Publication date: July 14, 2011Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Amos B. Smith, III, Simon J. Shaw, David C. Myles
-
Patent number: 7655808Abstract: Leptomycin-type compounds according to formula I wherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity.Type: GrantFiled: September 30, 2008Date of Patent: February 2, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Steven D. Dong, Daniel V. Santi, David C. Myles, Brian Hearn
-
Patent number: 7582611Abstract: Compounds having a structure according to formula (I) where RA, RB, RC, RD, RE, and RF are as defined herein, are useful as prokinetic agents.Type: GrantFiled: May 2, 2006Date of Patent: September 1, 2009Assignee: Pfizer Inc.Inventors: Yaoquan Liu, Christopher Carreras, David C. Myles, Yong Li, Simon James Shaw, Hong Fu, Yue Chen, Hao Zheng, Yandong Li, Mark A. Burlingame
-
Publication number: 20090111869Abstract: The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.Type: ApplicationFiled: June 18, 2008Publication date: April 30, 2009Applicant: Kosan Biosciences, Inc.Inventors: Daniel SANTI, David C. Myles, Zong-Qiang Tian, C. Richard Hutchinson, Robert Johnson, Yi-Qing Zhou, Li Feng
-
Publication number: 20090042837Abstract: Leptomycin-type compounds according to formula I wherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity.Type: ApplicationFiled: September 30, 2008Publication date: February 12, 2009Inventors: Steven Dong, Daniel V. Santi, David C. Myles, Brian Hearn
-
Patent number: 7446196Abstract: Leptomycin-type compounds according to Formula I wherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity.Type: GrantFiled: June 1, 2005Date of Patent: November 4, 2008Assignee: Kosan Biosciences, IncorporatedInventors: Steven Dong, Daniel V. Santi, David C. Myles, Brian Hearn